Sekisui Diagnostics‘ (Burlington, Mass.) microbial CDMO business announces it has completed construction of its £15.7 million ($20.7 million) cGMP capacity expansion at its U.K. site for clinical-grade drug substance manufacturing. Following appropriate licensure, this expansion will enable manufacturing capabilities for common drug types including enzymes, proteins and antibody fragment therapies, as well as plasmids and enzymes for cutting-edge gene therapy manufacture.
BioProduction by Sekisui is Sekisui Diagnostics’ contract service offering as a fermentation-focused CDMO with expertise in proteins and downstream purification. Their microbial process development and production experience helps smooth technical transfer and process scale-up. The new Grade C microbial fermentation and purification suites will accommodate production scales up to 1,000 L.
A Fermentation Gantry at Sekisui Diagnostics’ site (Source: Sekisui)
“This investment supports the vision and mission of Sekisui Diagnostics and the broader Sekisui Medical Group by enabling the continued growth of our share of the biologics CDMO market,” said Robert Schruender, President & CEO of Sekisui Diagnostics. “We look forward to working with biopharma companies seeking an experienced partner at a time when demand is outstripping manufacturing capacity.”
Louise Digby, Vice President, Enzymes & BioProduction at Sekisui Diagnostics added: “Over many years we have honed our technical and operational competency and expertise in enzyme production and microbial fermentation to serve our partners globally. This cGMP expansion enables us to support a broader customer base and expand our offering to existing customers.”